TY - JOUR
T1 - Augmentation strategy with olanzapine in resistant obsessive compulsive disorder
T2 - An Italian long-term open-label study
AU - Marazziti, Donatella
AU - Pfanner, Chiara
AU - Dell'Osso, Bernardo
AU - Ciapparelli, Antonio
AU - Presta, Silvio
AU - Corretti, Giorgio
AU - Di Nasso, Elena
AU - Mungai, Francesco
AU - Dell'Osso, Liliana
PY - 2005/7
Y1 - 2005/7
N2 - The present study reports the results of an open-label trial on the use of the combination of olanzapine (an atypical antipsychotic) + serotonin reuptake inhibitors (SRIs) in 26 resistant outpatients affected by resistant obsessive-compulsive disorder (OCD). All patients had been suffering from OCD, according to DSM IV criteria, for at least 2 years and had different comorbid disorders; they had been treated with an SRI at adequate dosages for at least 6 months, or had tried different augmentation strategies with no or poor response. As a result, olanzapine was added and continued for 1 year. After 12 weeks of this regimen, most of the patients (17) had shown a reduction in OC symptoms, as assessed by a decrease in the Yale-Brown Obsessive Compulsive Scale total score, which continued throughout subsequent months. Only mild side-effects were recorded and no patient halted the treatment. The addition of olanzapine would appear to be a useful short- and long-term strategy for augmenting SRI effectiveness in resistant OCD patients, especially in those presenting comorbidity with bipolar disorders.
AB - The present study reports the results of an open-label trial on the use of the combination of olanzapine (an atypical antipsychotic) + serotonin reuptake inhibitors (SRIs) in 26 resistant outpatients affected by resistant obsessive-compulsive disorder (OCD). All patients had been suffering from OCD, according to DSM IV criteria, for at least 2 years and had different comorbid disorders; they had been treated with an SRI at adequate dosages for at least 6 months, or had tried different augmentation strategies with no or poor response. As a result, olanzapine was added and continued for 1 year. After 12 weeks of this regimen, most of the patients (17) had shown a reduction in OC symptoms, as assessed by a decrease in the Yale-Brown Obsessive Compulsive Scale total score, which continued throughout subsequent months. Only mild side-effects were recorded and no patient halted the treatment. The addition of olanzapine would appear to be a useful short- and long-term strategy for augmenting SRI effectiveness in resistant OCD patients, especially in those presenting comorbidity with bipolar disorders.
KW - Atypical neuroleptics
KW - Augmentation strategies
KW - Obsessive-compulsive disorder
KW - Olanzapine
KW - Serotonin re-uptake inhibitors
UR - http://www.scopus.com/inward/record.url?scp=22344437675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22344437675&partnerID=8YFLogxK
U2 - 10.1177/0269881105053299
DO - 10.1177/0269881105053299
M3 - Article
C2 - 15982994
AN - SCOPUS:22344437675
VL - 19
SP - 392
EP - 394
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
SN - 0269-8811
IS - 4
ER -